Verve Medical

What Verve Medical does

Verve Medical is a privately-held U.S. medical device company headquartered in Scottsdale, Arizona, founded in 2010 and operating with 1-10 employees. The company is developing the Verve RPD™ System, an investigational catheter-based device that performs Renal Pelvic Denervation — a minimally invasive procedure in which radiofrequency energy is delivered via the urinary tract to deactivate overactive nerve fibers in the renal pelvis, with the goal of lowering blood pressure in patients whose hypertension remains uncontrolled despite multiple medications.

The technology is differentiated from incumbent renal denervation approaches by its access route (urinary tract rather than arterial) and its specific targeting of nerve fibers in and around the renal pelvis. The procedure is designed to take less than 30 minutes without major surgery, with most patients returning to normal activities within 1-2 days and no permanent implant required. Clinical validation rests on the TUSK feasibility trial, results of which were published in the Hypertension journal in 2022 and demonstrated an average systolic blood pressure reduction of approximately 20 mmHg at one year of follow-up.

Verve Medical is currently pre-revenue. Its commercial pathway is gated on regulatory clearance — the device is explicitly investigational and not cleared for distribution in any country — and its near-term go-to-market is structured around clinical trial recruitment via a self-serve patient eligibility survey on its website, feeding enrollment into a randomized, double-blinded U.S. pilot trial of 60 patients across 10 clinical sites that began in March 2026. Upon approval, the anticipated revenue model is one-time device sales to hospitals and healthcare facilities performing the procedure, addressing a U.S. addressable population estimated at 120 million hypertensive adults, of which approximately 93 million remain uncontrolled. Leadership consists of David B. Springer as President & CEO; the company maintains HIPAA, GDPR, and CCPA compliance postures.

Name

Verve Medical

Legal name

Verve Medical

Website

https://verve-medical.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

1–10 employees

Short description

Verve Medical is a Scottsdale-based medical device company developing the investigational Verve RPD™ System, a catheter-based renal pelvic denervation procedure that delivers radiofrequency energy via the urinary tract to lower blood pressure in patients with uncontrolled hypertension.

Ownership category

akta.pro rank

Product category

Renal Denervation Medical Devices / Interventional Hypertension Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)

Keywords

• Renal denervation devices
• Hypertension treatment
• Catheter-based ablation
• Minimally invasive medical devices
• Radiofrequency ablation systems

Headquarters

HQ city

Scottsdale

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Medical Device Sales: Verve Medical is a medical device company developing the Verve RPD System for renal pelvic denervation. The device is currently an investigational device not yet cleared for distribution in any country. Revenue model would likely involve device sales to hospitals and healthcare facilities upon regulatory approval.

Distribution channels1 record

Marketing channels1 record

Core offering

Verve Medical develops the Verve RPD (Renal Pelvic Denervation) System, an investigational catheter-based medical device that delivers radiofrequency energy via the urinary tract to deactivate overactive renal nerves, with the goal of lowering blood pressure in patients with uncontrolled (resistant) hypertension. The system is currently in clinical/regulatory development and is not yet commercially available.

Product overview

Verve Medical offers a single core product: the Verve RPD™ System, an investigational renal pelvic denervation device. This system provides a minimally invasive, energy-based treatment alternative for patients whose hypertension remains uncontrolled despite medication. The procedure involves inserting a thin catheter through the urinary tract to deliver radiofrequency energy to renal nerves, with the entire procedure taking less than 30 minutes.

Differentiator

Problem solved

Functional benefit

Products and services

• Verve RPD System (Renal Pelvic Denervation System) Investigational catheter-based medical device that delivers radiofrequency energy through the urinary tract to deactivate overactive renal nerves in order to lower blood pressure in patients with uncontrolled (resistant) hypertension. Intended for use by interventional specialists in hospitals and clinical trial sites.

Quantifiable outcome

• Average reduction of approximately 20 mmHg in systolic blood pressure through one year of follow-up (TUSK feasibility trial)
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators3 records

Recent moves3 records

Expansion highlights3 records

Emerging players

• Sonivie: Clinical-stage developer of ultrasound-based renal denervation (TIVUS system) for hypertension. Competes in the same RDN space with an alternative energy modality.
• Procept BioRobotics: Developer of the Aquablation system, which uses a robotic waterjet via the urinary tract to treat BPH. Comparable because it shares Verve's urinary-tract access model and minimally invasive outpatient positioning, though in a different indication.

Broad incumbents

• Medtronic: Markets the Symplicity Spyral renal denervation system, the leading arterial RDN platform globally. A broad incumbent with a large-scale commercial and clinical infrastructure competing directly for the same patient population.
• Boston Scientific: A diversified medical device incumbent that previously marketed the Vessix renal denervation system. Represents a potential strategic acquirer and a historical competitor in RDN.

Direct peers

• Recor Medical: Developer of the Paradise ultrasound renal denervation system for hypertension. Most direct competitor to Verve in the renal denervation category, with similar patient population and clinical positioning.
• Kona Medical: Historically developed external ultrasound-based renal denervation for hypertension. Operates in the same RDN therapeutic category targeting resistant/uncontrolled hypertension.
• Ablative Solutions: Developer of a chemical renal denervation approach (Peregrine System) targeting uncontrolled hypertension. Competes in the same RDN space with an alternative ablation modality.
• Mercator MedSystems: Developer of catheter-based local drug delivery and denervation therapies including in the renal hypertension space. A direct peer in minimally invasive renal intervention technology.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/verve-medical

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Verve Medical